

## Til Københavns Fondsbørs

### P R E S S E M E D D E L E L S E

#### **ZGene A/S indgår aftale med det amerikanske biotech selskab Lentigen Corporation**

Lentigen opnår eksklusiv licens til specifikke ZGene multisubstrat kinasegen til udvikling af bedre og mere sikker behandling af patienter, der modtager knoglemarvstransplantation.

ZGene modtager upfront betalinger og yderligere milepælsbetalinger baseret på succesfuld udvikling og kommercialisering samt royalty betalinger af markedsførte produkter. Der er ikke oplyst yderligere aftalebetingelser.

Se venligst vedhæftet pressemeddelelse fra ZGene.

Kontaktperson: Zoran Gojkovic, adm. direktør  
Telefon: 4525 9220

NeuroSearch er et børsnoteret biofarmaceutisk selskab. NeuroSearch har fem stoffer i klinisk udvikling: NS2359 til behandling af depression og ADHD (fase II) i samarbejde med GSK, NS2330 til behandling Parkinsons sygdom (fase II) i samarbejde med Boehringer Ingelheim, egen udvikling af NS1209 til behandling af epilepsi (fase II) og smerte (fase I), ABT-894 til behandling af smerte (fase I) i samarbejde med Abbott og Endovion til behandling af kræft (fase I) i samarbejde med TopoTarget. NeuroSearch har endvidere en portefølje af prækliniske udviklingskandidater og forskningsprogrammer primært fokuseret på ion-kanal modulatorer med kommercielt potentiale inden for CNS og andre sygdomme. NeuroSearch har desuden aktiebesiddelser i flere biotekselskaber: Atonomics A/S, Bavarian Nordic A/S, NsGene A/S, Sophion Bioscience A/S, ZGene A/S og PainCeptor Pharma Corporation Inc.



NEWS RELEASE

**ZGENE A/S AND LENTIGEN CORPORATION ENTER LICENSE AGREEMENT FOR SELECTED  
ZGENE INTELLECTUAL PROPERTY**

*ZGene Grants Exclusive, World-Wide License to Multisubstrate Kinase Gene  
Technology*

**Denmark and Maryland, USA** January 3, 2006 – ZGene A/S and Lentigen Corporation announced today they have entered into an agreement whereby Lentigen will obtain an exclusive license to specified proprietary ZGene multisubstrate kinase genes for certain indications using lentivirus. These genes will allow Lentigen to create lentiviral vectors with increased safety by providing the capability to eliminate genetically modified cells from the body, when required. Lentigen will firstly develop products aiming at providing better and safer treatments for patients receiving bone marrow transplants. ZGene will receive an upfront payment and additional milestone payments based on successful development and commercialization, as well as royalty payments on resulting products. No additional terms of the agreement were disclosed.

The CEO of ZGene, Zoran Gojkovic says: “This agreement is another commercial validation of our technology. Since the founding of the company, we have been purposefully and successfully expanding our gene portfolio to ensure that this technology remains at the forefront of drug activation. I am excited that Lentigen will combine our novel genes with lentiviral delivery and expect that the combined technologies will pave the way for better and safer treatments of patients”.

“This license agreement represents another important step in Lentigen’s development,” remarked Dr. Boro Dropulic, Founder and CEO of Lentigen. “We believe that these genes will provide lentiviral vector technology with additional safety features not present in retroviral and lentiviral vectors currently under evaluation in human clinical trials. Lentigen aims to increase the safety of Lentiviral vector technology by the acquisition of technologies and by its own internal research and development efforts.”

### **About ZGene A/S**

ZGene A/S is a privately held Danish biotechnology company founded in 2001. ZGene A/S holds the rights for a prodrug activation system, called ZAS™, which drastically enhances the effect of current anticancer and antiviral drugs and reduces their toxicity. ZGene collaborates with leading academic and industrial partners in the field of cancer therapy and innovative gene delivery. ZGene is based in the Medicon Valley Region in Denmark. The company was founded by private investors, NsGene A/S, and NeuroSearch A/S. Dansk Innovationsinvestering I/S and Symbion Capital I has since entered the company through capital investments. <http://www.zgene.dk>

### **About Lentigen Corporation**

Lentigen Corporation is a privately owned biotechnology company focused on the manufacturing and development of lentiviral vectors using its proprietary gene delivery technology for a wide range of applications in biotechnology and medicine. Lentiviral vectors are highly adapted delivery vehicles that can transport genes or gene silencing sequences into cells with high efficiency and stability. Lentigen is positioning itself to become the leading provider of Lentiviral vector products and services for academic, government, biotechnology and pharmaceutical researchers. For further information, visit [www.Lentigen.com](http://www.Lentigen.com).

#### Contacts:

ZGene A/S  
Zoran Gojkovic, CEO  
Tel.: 0045 4525 9220  
[zg@zgene.net](mailto:zg@zgene.net)

Lentigen Corporation  
Greg Feulner, VP Business Development  
Tel: 001 443 543 5318  
[greg.feulner@lentigen.com](mailto:greg.feulner@lentigen.com)